Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak

Environmental Science and Technology

Volumn 46, Issue 23, 2012, Pages 12873-12881

  Azuma, Takashi ^a   Nakada, Norihide ^a   Yamashita, Naoyuki ^a   Tanaka, Hiroaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ATTENUATION RATE; DILUTION RATE; ENVIRONMENTAL WATER; MATHEMATICAL PRINCIPLE; OSELTAMIVIR; OSELTAMIVIR CARBOXYLATE; REMOVAL RATE; RIVER BASINS; RIVER WATER; SYNCHRONOUS DYNAMICS; TAMIFLU; TIME-DEPENDENT DYNAMICS;

AMINES; CARBOXYLATION; DYNAMICS; INFORMATION DISSEMINATION; PATIENT MONITORING; SEWAGE TREATMENT PLANTS;

RIVERS;

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; OSELTAMIVIR; RIVER WATER; ZANAMIVIR;

CHEMICAL CONTROL; DISEASE CONTROL; DISEASE SPREAD; DRUG; INFLUENZA; PREDICTION; RIVER WATER; SEWAGE; SYNCHRONY; TEMPORAL PERIOD; TIME DEPENDENT BEHAVIOR; WASTE TREATMENT;

ARTICLE; EPIDEMIC; JAPAN; MATHEMATICAL ANALYSIS; RIVER BASIN; SEASONAL INFLUENZA; WATER TREATMENT;

AMANTADINE; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; ENVIRONMENTAL MONITORING; HUMANS; INFLUENZA, HUMAN; JAPAN; OSELTAMIVIR; RIVERS; SEWAGE; WATER POLLUTANTS, CHEMICAL; ZANAMIVIR;

HONSHU; JAPAN; KINKI; YODO BASIN;

EID: 84870547958     PISSN: 0013936X     EISSN: 15205851     Source Type: Journal    
DOI: 10.1021/es303203c     Document Type: Article

References (59)

1. Sugaya, N.; Mitamura, K.; Yamazaki, M.; Tamura, D.; Ichikawa, M.; Kimura, K.; Kawakami, C.; Kiso, M.; Ito, M.; Hatakeyama, S.; Kawaoka, Y. Lower clinical effectiveness of Oseltamivir against Influenza B contrasted with Influenza A infection in children Clin. Infect. Dis. 2007, 44 (2) 197-202
2. Hoffmann-La Roche Inc. Nutley, N. J. Roche Research Report; Pediatric Advisory Committee Executive Summary for Tamiflu, 2005; pp 1-22.
3. George, H.; Joseph, M.; Penelope, W. Clinical pharmacokinetics of the prodrug Oseltamivir and its active metabolite Ro 64-0802 Clin. Pharmacokinet. 1999, 37 (6) 471-484
4. Ellis, J. B. Antiviral pandemic risk assessment for urban receiving waters Water Sci. Technol. 2010, 61 (4) 879-884
5. Tamiflu (Oseltamivir Phosphate) Capsules and for Oral Suspension. Complete Production Information; Roche Laboratories Inc.: Nutley, New Jersey, 2008; pp 1-23.
6. WHO. Pandemic influenza preparedness and response: A WHO guidance document. http://www.who.int/en/ (accessed July 30, 2012).
7. Centersfor Disease Controland Prevention (CDC). Antiviral Agents for Influenza. http://www.cdc.gov/flu/professionals/antivirals/antiviral-agents-flu. html (accessed July 30, 2012).
8. Bright, R. A.; Shay, D. K.; Shu, B.; Cox, N. J.; Klimov, A. I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States JAMA, J. Am. Med. Assoc. 2006, 295 (8) 891-894
9. Fick, J.; Lindberg, R. H.; Tysklind, M.; Haemig, P. D.; Waldenström, J.; Wallensten, A.; Olsen, B. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: Implications for development of resistance by influenza A virus PLoS One 2007, 2 (10) e986
10. Bartels, P.; von Tümpling, W., Jr. The environmental fate of the antiviral drug oseltamivir carboxylate in different waters Sci. Total Environ. 2008, 405 (1-3) 215-225
11. Straub, J. O. An environmental risk assessment for oseltamivir (Tamiflu®) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions Ecotoxicol. Environ. Saf. 2009, 72 (6) 1625-1634
12. Gonņalves, C.; Pérez, S.; Osorio, V.; Petrovic, M.; Alpendurada, M. F.; Barceló, D. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: Kinetics, identification of the transformation products, and environmental occurrence Environ. Sci. Technol. 2011, 45 (10) 4307-4314
13. Accinelli, C.; Caracciolo, A. B.; Grenni, P. Degradation of the antiviral drug oseltamivir carboxylate in surface water samples Int. J. Environ. Anal. Chem. 2007, 87 (8) 579-587
14. Saccà, M., Ludovica; Accinelli, C.; Fick, J.; Lindberg, R.; Olsen, B. Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems Chemosphere 2009, 75 (1) 28-33
15. Accinelli, C.; Saccà Maria, L.; Fick, J.; Mencarelli, M.; Lindberg, R.; Olsen, B. N. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments Chemosphere 2010, 79 (8) 891-897
16. Ghosh, G. C.; Nakada, N.; Yamashita, N.; Tanaka, H. Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants Chemosphere 2010, 81 (1) 13-17
17. Leknes, H.; Sturtzel, I. E.; Dye, C. Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic Sci. Total Environ. 2012, 414 (0) 632-638
18. Prasse, C.; Schlüsener, M. P.; Schulz, R.; Ternes, T. A. Antiviral drugs in wastewater and surface waters: A new pharmaceutical class of environmental relevance? Environ. Sci. Technol. 2010, 44 (5) 1728-1735
19. Matsuo, H.; Sakamoto, H.; Arizono, K.; Shinohara, R. Behavior of pharmaceuticals in waste water treatment plant in Japan Bull. Environ. Contam. Toxicol. 2011, 87 (1) 31-35
20. Takanami, R.; Ozaki, H.; Giri Rabindra, R.; Taniguchi, S.; Hayashi, S. Detection of antiviral drugs oseltamivir phosphate and oseltamivir carboxylate in Neya river, Osaka, Japan J. Wat. Environ. Technol. 2010, 8 (4) 363-372
21. Ghosh, G. C.; Nakada, N.; Yamashita, N.; Tanaka, H. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan Environ. Health Perspect. 2010, 118 (1) 103-107
22. Söderström, H.; Järhult, J. D.; Olsen, B.; Lindberg, R. H.; Tanaka, H.; Fick, J. Detection of the antiviral drug Oseltamivir in aquatic environments PLoS ONE 2009, 4 (6) e6064
23. Hutchinson, T. H.; Beesley, A.; Frickers, P. E.; Readman, J. W.; Shaw, J. P.; Straub, J. O. Extending the environmental risk assessment for oseltamivir (Tamiflu®) under pandemic use conditions to the coastal marine compartment Environ. Int. 2009, 35 (6) 931-936
24. GlaxoSmithKline. Zanamivir. Safety Data Sheet, Ver.13, 2006, ' pp 1-8.
25. Kawakami, T.; Yamashita, N.; Nakada, N.; Tanaka, H. In Initial Ecological Risk Assessment of Pharmaceuticals and Personal Care Products Found in the Japanese Water Environment Using Algae, Daphnia and Bacteria; Micropol & Ecohazard, University of New South Wales: Sydney, NSW, Australia., 11-13 July, 2011.
26. Singer, A. C.; Nunn, M. A.; Gould, E. A.; Johnson, A. C. Potential risks associated with the proposed widespread use of Tamiflu Environ. Health Perspect. 2007, 115 (1) 102-106
27. Järhult, J. D.; Muradrasoli, S.; Wahlgren, J.; Söderström, H.; Orozovic, G.; Gunnarsson, G.; Bröjer, C.; Latorre-Margalef, N.; Fick, J.; Grabic, R.; Lennerstrand, J.; Waldenström, J.; Lundkvist, Å.; Olsen, B. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards PLoS One 2011, 6 (9) e24742
28. Renner, R. Tamiflu survives sewage treatment Environ. Sci. Technol. 2007, 41 (22) 7591
29. Singer, A. C.; Howard, B. M.; Johnson, A. C.; Knowles, C. J.; Jackman, S.; Accinelli, C.; Caracciolo, A. B.; Bernard, I.; Bird, S.; Boucard, T.; Boxall, A.; Brian, J. V.; Cartmell, E.; Chubb, C.; Churchley, J.; Costigan, S.; Crane, M.; Dempsey, M. J.; Dorrington, B.; Ellor, B.; Fick, J.; Holmes, J.; Hutchinson, T.; Karcher, F.; Kelleher, S. L.; Marsden, P.; Noone, G.; Nunn, M. A.; Oxford, J.; Rachwal, T.; Roberts, N.; Roberts, M.; Sacca, M. L.; Sanders, M.; Straub, J. O.; Terry, A.; Thomas, D.; Toovey, S.; Townsend, R.; Vouivoulis, N.; Watts, C. Meeting report: Risk assessment of Tamiflu use under pandemic conditions Environ. Health Perspect. 2008, 116 (11) 1563-1567
30. Singer, A. C.; Johnson, A. C.; Anderson, P. D.; Snyder, S. A. Reassessing the risks of Tamiflu use during a pandemic to the lower Colorado River Environ. Health Perspect. 2008, 116 (7) A285-A286
31. Singer, A. C.; Colizza, V.; Schmitt, H.; Andrews, J.; Balcan, D.; Huang, W. E.; Keller, V. D. J.; Vespignani, A.; Williams, R. J. Assessing the ecotoxicologic hazards of a pandemic influenza medical response Environ. Health Perspect. 2011, 119 (8) 1084-1090
32. Straub, J. O.; F. Hoffmann-La Roche Ltd. Ecotoxicology in the context of the environmental risk assessment for Tamiflu. http://www.bafu.admin.ch/ (accessed July 30, 2012).
33. Takanami, R.; Taniguchi, S.; Giri Rabindra, R.; Hayashi, S.; Ozaki, H. In Antiviral Drugs Zanamivir and Oseltamivir Found in Wastewater and Surface Water in Osaka, Japan. In The 4th IWA-ASPIRE Conference & Exhibition -Towards Sustainable Water Supply and Recycling Systems, 2011.
34. Lindsey, M. R.; Cass, C. E.; Alan, B. Pharmacokinetics of Zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers Clin. Pharmacokinet. 1999, Suppl.36 (6) 1-11
35. Massarella, J. W.; He, G. Z.; Dorr, A.; Nieforth, K.; Ward, P.; Brown, A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers J. Clin. Pharmacol. 2000, 40 (8) 836-843
36. Ort, C.; Lawrence, M. G.; Rieckermann, J. g.; Joss, A. Sampling for pharmaceuticals and personal cre products (PPCPs) and illicit Drugs in wastewater systems: Are your conclusions valid? A critical review Environ. Sci. Technol. 2010, 44 (16) 6024-6035
37. Lindegårdh, N.; Hien, T. T.; Farrar, J.; Singhasivanon, P.; White, N. J.; Day, N. P. J. A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu® J. Pharm. Biomed. Anal. 2006, 42 (4) 430-433
38. Product Monograph Tamiflu; F. Hoffmann-La Roche Ltd.: Mississauga, Ontario, Canada, 2008.
39. SPARC On-Line Calculator v4.6, University of Georgia, Atlanta, GA. 2011. http://sparc.chem.uga.edu/sparc/ (accessed July 30, 2012).
40. Goralski, K. B.; Smyth, D. D.; Sitar, D. S. In vivo analysis of amantadine renal clearance in the uninephrectomized rat: Functional significance of in vitro bicarbonate-dependent amantadine renal tubule transport J. Pharmacol. Exp. Ther. 1999, 290 (2) 496-504
41. Rogers, H. R. Sources, behaviour and fate of organic contaminants during sewage treatment and in sewage sludges Sci. Total Environ. 1996, 185 (1-3) 3-26
42. Henkel, J. G.; Hane, J. T.; Gianutsos, G. Structure-anti-parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution J. Med. Chem. 1982, 25 (1) 51-56
43. Kumar, V.; Nakada, N.; Yasojima, M.; Yamashita, N.; Johnson, A. C.; Tanaka, H. Rapid determination of free and conjugated estrogen in different water matrices by liquid chromatography-tandem mass spectrometry Chemosphere 2009, 77 (10) 1440-1446
44. Okuda, T.; Yamashita, N.; Tanaka, H.; Matsukawa, H.; Tanabe, K. Development of extraction method of pharmaceuticals and their occurrences found in Japanese wastewater treatment plants Environ. Int. 2009, 35 (5) 815-820
45. Kyoto Prefecture Infectious Disease Surveillance Center,J. Infectious Deseases Weekly Report (in Japanase). http://www.pref.kyoto.jp/idsc/index.html (accessed July 30, 2012).
46. Chugai Pharmaceutical Co., L. Interview form for Tamiflu(in Japanse). http://www.tamiflu-j.com/tamiflu-j/02/0201.html (accessed July 30, 2012).
47. Azuma, T.; Ghosh, G. C.; Nakada, N.; Yamashita, N.; Tanaka, H. In Levels of Antivirus Drugs at Sewage Treatment Plants and Effectiveness of Treatment in Relation to the New Type of Influenza. In IWA World Water Congress & Exhibition, Montréal 2010, Canada, 2010.
48. Tong, A. Y. C.; Braund, R.; Tan, E. W.; Tremblay, L. A.; Stringer, T.; Trought, K.; Peake, B. M. UV-induced photodegradation of oseltamivir (Tamiflu) in water Environ. Chem. 2011, 8 (2) 182-189
49. Razonable, R. R. Antiviral drugs for viruses other than human immunodeficiency virus Mayo Clin. Proc. 2011, 86 (10) 1009-1026
50. Hoffmann-LaRocheInc., Further expansion of Tamiflu manufacturing capacity. Roche Media Release 2005 2005.
51. UppsalaUniversity Science Daily. What Is the fate and effects of influenza drug tamiflu in environment? http://www.sciencedaily.com/releases/ 2008/11/081126163722.htm (accessed July 30, 2012).
52. Ministry of Health, Labour and Welfare. Japan. Status of use of anti-influenza drugs for flu patients (in Japanese). http://www.mhlw.go.jp/ (accessed July 30, 2012).
53. Healthy Nippon 21 Council Secretariat. Japan Survey about influenza in an effort to promote risk management for health (in Japanese). http://www.kenko-nippon21forum.gr.jp/free/ (accessed July 30, 2012).
54. Hashimoto, S.; Murakami, Y.; Taniguchi, K.; Shindo, N.; Osaka, K.; Fuchigami, H.; Nagai, M. Annual incidence rate of infectious diseases estimated from sentinel surveillance data in Japan J. Epidemiol./Jpn Epidemiol. Assoc. 2003, 13 (3) 136-141
55. Kawado, M.; Hashimoto, S.; Murakami, Y.; Izumida, M.; Ohta, A.; Tada, Y.; Shigematsu, M.; Yasui, Y.; Taniguchi, K.; Nagai, M. Annual and weekly incidence rates of influenza and pediatric diseases estimated from infectious disease surveillance data in Japan, 2002-2005 J. Epidemiol. 2007, 17 (Supplement) S32-S41
56. Infectious Disease Surveillance Center, J. Infectious DeseasesWeekly Report (IDWR) (in Japanase). http://idsc.nih.go.jp/index-j.html (accessed July 30, 2012).
57. Infectious Disease Surveillance Center, J. Infectious Deseases Weekly Report (IDWR). http://idsc.nih.go.jp/idwr/index-e.html (accessed July 30, 2012).
58. Japan Sewage Works Association. Statistics of Sewerage (in Japanese). 2010.
59. Accinelli, C.; Saccà, M. L.; Mencarelli, M.; Vicari, A. Application of Bioplastic moving bed biofilm carriers for the removal of synthetic pollutants from wastewater Bioresour. Technol. 2012, 120 (0) 180-186